Comparison of oral itasetron with oral ondansetron: Results of a double- blind, active-controlled phase II study in chemotherapy-naive patients receiving moderately emetogenic chemotherapy

Anti-Cancer Drugs

Volumn 8, Issue 5, 1997, Pages 436-444

  Goldschmidt, Hartmut ^a   Salwender, Hans ^a   Egerer, Gerlinde ^a   Kempe, Rudolf ^b   Voigt, Thor ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Chemotherapy; Efficacy; Emesis; Itasetron; Ondansetron; Safety

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPIRUBICIN; ITASETRON; ONDANSETRON; SEROTONIN ANTAGONIST;

ADULT; AGED; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING; XEROSTOMIA;

EID: 0030859247     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199706000-00004     Document Type: Article

References (49)

1. Coates A, Abraham S, Kaye SB, et al. On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 203-8.
2. Parliament MB, Danjoux CE, Clayton T. Is cancer treatment toxicity accurately reported? Int J Radiat Oncol Biol Phys 1985; 11: 603-8.
3. Triozzi PL, Laszlo J. Optimum management of nausea and vomiting in cancer chemotherapy. Drugs 1987; 34: 136-9.
4. Laszlo J, Lucas VS Jr. Emesis as a critical problem in chemotherapy (editorial). N Engl J Med 1981; 305: 948-9.
5. Laszlo J, et al. Nausea and vomiting as major complications of cancer chemotherapy. Drugs 1983; 25 (suppl 1): 1-7.
6. Marty M, Pouillart P, Scholl P, et al. Comparison of the 5-hydroxtryptamine (serotonin) antagonist ondansetron (GR 38032 F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990; 322: 816-21.
7. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990; 322: 810.
8. Kris MG, Gralla RJ, Clark RA, et al. Incidence course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985; 3: 1379-84.
9. Gralla RJ, Tyson LB, Kris MG, et al. The management of chemotherapy-induced nausea and vomiting. Med Clin North Am 1987; 71: 289-301.
10. Craig JB, Powell BL. Review: the management of nausea and vomiting in clinical oncology. Am J Med Sci 1983; 293: 34-44.
11. Fetting JH, Grochow LB, Felstein MF, et al. The course of nausea and vomiting after high dose cyclophosphamide. Cancer Treat Rep 1982; 66: 1487-93.
12. Roila F, Tonaton M, Basurto C, et al. Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolonge versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the italian oncology group for clinical research. J Clin Oncol 1989; 7: 1693-700.
13. Roila F, Boschetti E, Tonato M, et al. Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. Am J Clin Oncol 1991; 14: 238-42.
14. Morrow GR. Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst 1982; 68: 585-8.
15. Smyth JF. The problem of emesis induced by cancer chemotherapy. Clinician 1988; 6: 2-12.
16. Fozard JR, Mobarok Ali ATM. Blockade of neuronal tryptamine receptors by metoclopramide. Eur J Pharmacol 1978; 49: 109-12.
17. Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986; 88: 497-9.
18. Kilpatrick GJ, Jones BJ, Tyers MB. Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 1987; 330: 746-8.
19. Costall B, Domeney AM, Gunning SJ. GR38032F: a potent and novel inhibitor of cisplatin-induced (abstract). Br J Pharmacol 1987; 90: 90.
20. 3 antagonist, GR38032F. Cancer Treat Res 1987; 14: 333-6.
21. 3 receptor antagonist, can abolish emesis induced by cyclophosphamide or radiation in the ferret. Br J Pharmacol 1987; 91 (suppl): 417.
22. Markham A, Sorkin EM. Ondansetron: an update of its therapeutic use in chemotherapy induced and post-operative nausea and vomiting. Drugs 1993; 45: 9316-52.
23. Schalhorn B. Systematic pain treatment in children with tumours. Fortschritt Med 1992; 110: 60-3.
24. Schmoll HJ. Introduction: the clinical challenge. Eur J Cancer 1991; 27 (suppl 1): 1-2.
25. Levitt M, Warr D, Yelle L, et al. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate and fluorouracil. N Engl J Med 1993; 328: 1081-4.
26. Ballard HS, Bottino G, Bottino J. Ondansetron and chest pain. Lancet 1992; 340: 1107.
27. 3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation Cancer Chemother Pharmacol 1991; 28: 470-4.
28. Roila F, Del Favero A. Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 1995; 29: 95-109.
29. Schiantarelli P, Marini MG, Vidi A, et al. Pharmacokinetic properties in experimental animals and volunteers of DAU 6215, a 5-HT3 receptor antagonist indicated for emesis induced by anticancer therapy. In: Bianchi AL, Grélot AD, Miller GI, eds. Mechanisms and control of emesis. Paris: John Libbey 1992; 223: 227-33.
30. Brown GW. Ondansetron and chemotherapy-induced emesis. In: Marty M, ed. Proc Int Congr on Chemotherapy Neoadjuvants 3. Berlin: Springer 1991: abstr.
31. Hartung J. Statistik. München: Oldenbourg 1982: 205.
32. Dicato MA. Oral treatment with ondansetron in an outpatient setting. Eur J Cancer 1991; 27 (suppl 1): 18-9.
33. Jones AL, Cunningham D. The clinical care of patients receiving chemotherapy. In: Andrews PLR, Sanger GJ, eds. Emesis in anti-cancer therapy. Mechanisms and treatment. London: Chapman & Hall 1993; 11: 229-46.
34. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomized study. Eur J Cancer 1993; 29A: 1669-72.
35. Gebbia V, Cannata G, Testa A, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer 1994; 7: 1945-52.
36. Fauser A, Bleiberg H, Chevallier B, et al. A double-blind randomized comparative trial of iv dolasetron (D) vs iv metoclopramide (M) in prevention of emesis in moderately-emetogenic chemotherapy (CT). Proc Am Soc Clin Oncol 1995; 14: A1748 (abstr).
37. Bertheault-Cvitkovic F, Tubiana-Hulin M, Chevalier B, Clavel M, Rossy JF, Warrell RP. Gallium nitrate (GN) vs pamidronate (APD) for acute control of cancer-related hypercalcemia (CRH): interim results of a randomized, double-blind, multi-national study. Proc Am Soc Clin Oncol 1995; 14: A369 (abstr).
38. 3 antagonist, in cancer patients treated with cisplatin. Annu J Clin Oncol 1994; 17: 97-102.
39. Tonato M, Roila F, Del Favero A. Methodology of antiemetic trials: a review. Ann Oncol 1991; 2: 107-14.
40. Bécouarn Y, Bui NB, David M, Lakdja F, Brunet R, Chauvergne J. Improved control of cisplatin-induced emesis with a combination of high doses of methylprednisolone and metoclopramide: a single-blind randomized trial. Eur J Cancer Clin Oncol 1986; 22: 1421-4.
41. Alba E, Batus R, Castro I, Ojeda B, Andrés L de. Metoclopramida más difenhidramina frente a clorpromacina en los vómitos inducidos por cisplatino. Estudio aleatorizado, cruzado y a doble ciego. Med Clin 1987; 89: 410-2.
42. Mellink WA, Blijham GH, van Deyk WA. Amitriptyline plus fluphenazine to prevent chemotherapy-induced emesis in cancer patients: a double-blind randomized crossover study. Eur J Cancer Clin Oncol 1994; 20: 1147-50.
43. Martin-Jimenez M, Diaz-Rubio E. Clinical evaluation of the simultaneous blockade of the dopamine D-2, histamine H-1, and muscarinic cholinergic receptors in cancer chemotherapy-induced emesis: results of a controlled trial. Cancer Chemother Pharmacol 1986; 18: 168-71.
44. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med 1993; 329: 1790-6.
45. Yarker YE, McTavish D. Granisetron - an update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy. Drugs 1994; 48: 761-93.
46. Lee CR, Plosker GL, McTavish D. Tropisetron - a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 1993; 46: 925-43.
47. Watanabe H, Hasegawa A, Shinozaki T, et al. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol 1995; 35: 278-82.
48. Morganroth J, McGinn C. Anti-arrhythmic effect of a 5-hydroxytryptamine M-receptor antagonist, ICS 205-930. Am J Cardiol 1988; 61: 470-1.
49. Audhuy B, Cappelaere P, Martin M, et al. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 1996; 32A: 807-13.